Hernia Repair: No Simple Solution
Hernia repair is a staple of the general surgeon’s practice, with more than two million procedures performed annually worldwide. However, the procedure has proven problematic due to the mesh products used to repair the hernia defect and their potential to cause complications over time. At the Fifth International Hernia Congress, held recently in New York City, physicians debated the pros and cons of the many hernia repair mesh products that are now available. Although the general consensus at the meeting was there is no “ideal mesh,” mesh manufacturers continue to innovate in this field, offering a host of new products for this $500+ million market, including a variety of biologic meshes for complex repairs, synthetic meshes with biologic-like properties, fully resorbable meshes, and meshes with bacteriostatic properties.
Keep up with the top medtech business and regulatory news.
More from Archive
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
REUSE OF DISPOSABLE CARDIAC CATHETERS TARGETED BY FDA in an effort to address safety concerns about reuse of single-use products. The cardiac catheter product area "seems to jump up as one that is an area for us to focus on," Larry Spears, director of the Office of Compliance's Division of Enforcement III in FDA's Center for Devices and Radiological Health, said June 24 at a Food Drug and Law Institute conference held in Washington, D.C.
St Jude Medical and Spire are to develop anti-bacterial heart valve sewing cuffs using Spire's Spi-Argent silver coating process. The agreement covers a variety of valve designs as well as ancillary components. The treatment is aimed at reducing the incidence of endocarditis, a rare but dangerous complication of valve transplant which has a mortality rate as high as 60%.
Nissho saw sales rise only 1% to ¥17 billion ($930 million) in the year to March 1997. The Japanese company's net income was Yen3 billion, compared with Yen1.7 billion for the previous year, reports Reuters. Nissho produces disposable medical equipment.
More from Medtech Insight
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.